This review evaluates the evidence for p-tau217 as a peripheral biomarker of AD, compares it to other phosphorylated tau biomarkers, explores its relationship with imaging methods, and examines its utility in AD diagnosis and prognosis. Here, MAPT is linked to Alzheimer disease.